117 related articles for article (PubMed ID: 29526801)
21. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
22. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
23. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
[TBL] [Abstract][Full Text] [Related]
24. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Wang M; Wu W; Wu W; Rosidi B; Zhang L; Wang H; Iliakis G
Nucleic Acids Res; 2006; 34(21):6170-82. PubMed ID: 17088286
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
26. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
27. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
28. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
29. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
30. Ku DNA End-Binding Activity Promotes Repair Fidelity and Influences End-Processing During Nonhomologous End-Joining in
Emerson CH; Lopez CR; Ribes-Zamora A; Polleys EJ; Williams CL; Yeo L; Zaneveld JE; Chen R; Bertuch AA
Genetics; 2018 May; 209(1):115-128. PubMed ID: 29500182
[TBL] [Abstract][Full Text] [Related]
31. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.
Howard SM; Yanez DA; Stark JM
PLoS Genet; 2015 Jan; 11(1):e1004943. PubMed ID: 25629353
[TBL] [Abstract][Full Text] [Related]
32. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
33. The Human T-Cell Leukemia Virus Type 1 Basic Leucine Zipper Factor Attenuates Repair of Double-Stranded DNA Breaks via Nonhomologous End Joining.
Rushing AW; Hoang K; Polakowski N; Lemasson I
J Virol; 2018 Aug; 92(15):. PubMed ID: 29769340
[TBL] [Abstract][Full Text] [Related]
34. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
Soni A; Siemann M; Pantelias GE; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
[TBL] [Abstract][Full Text] [Related]
35. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells.
Kumar TS; Kari V; Choudhary B; Nambiar M; Akila TS; Raghavan SC
J Biol Chem; 2010 Oct; 285(42):32657-70. PubMed ID: 20699221
[TBL] [Abstract][Full Text] [Related]
36. Super-resolution imaging identifies PARP1 and the Ku complex acting as DNA double-strand break sensors.
Yang G; Liu C; Chen SH; Kassab MA; Hoff JD; Walter NG; Yu X
Nucleic Acids Res; 2018 Apr; 46(7):3446-3457. PubMed ID: 29447383
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
39. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
40. 14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2.
Chen Y; Li Z; Dong Z; Beebe J; Yang K; Fu L; Zhang JT
Mol Cancer Res; 2017 Apr; 15(4):418-428. PubMed ID: 28087741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
